MX2022001271A - Derivados de dihidropirimidina y usos de estos en el tratamiento de la infeccion por vhb o de enfermedades inducidas por vhb. - Google Patents

Derivados de dihidropirimidina y usos de estos en el tratamiento de la infeccion por vhb o de enfermedades inducidas por vhb.

Info

Publication number
MX2022001271A
MX2022001271A MX2022001271A MX2022001271A MX2022001271A MX 2022001271 A MX2022001271 A MX 2022001271A MX 2022001271 A MX2022001271 A MX 2022001271A MX 2022001271 A MX2022001271 A MX 2022001271A MX 2022001271 A MX2022001271 A MX 2022001271A
Authority
MX
Mexico
Prior art keywords
hbv
treatment
induced diseases
infection
dihydropyrimidine derivatives
Prior art date
Application number
MX2022001271A
Other languages
English (en)
Inventor
Zhanling Cheng
Zhiguo Liu
Yimin Jiang
Linglong Kong
Jianping Wu
Yanping Xu
Gang Deng
Chao Liang
Xiangjun Deng
Original Assignee
Janssen Sciences Ireland Unlimited Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland Unlimited Co filed Critical Janssen Sciences Ireland Unlimited Co
Publication of MX2022001271A publication Critical patent/MX2022001271A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

En la presente se proporcionan derivados de dihidropirimidina que son útiles en el tratamiento o la prevención de la infección por VHB o de enfermedades inducidas por VHB, más particularmente de la infección crónica por VHB o de enfermedades inducidas por la infección crónica por VHB, así como aplicaciones farmacéuticas o médicas de estos.
MX2022001271A 2019-07-31 2020-07-30 Derivados de dihidropirimidina y usos de estos en el tratamiento de la infeccion por vhb o de enfermedades inducidas por vhb. MX2022001271A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2019098575 2019-07-31
PCT/CN2020/105767 WO2021018239A1 (en) 2019-07-31 2020-07-30 Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases

Publications (1)

Publication Number Publication Date
MX2022001271A true MX2022001271A (es) 2022-05-03

Family

ID=74230250

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022001271A MX2022001271A (es) 2019-07-31 2020-07-30 Derivados de dihidropirimidina y usos de estos en el tratamiento de la infeccion por vhb o de enfermedades inducidas por vhb.

Country Status (10)

Country Link
US (1) US20220267313A1 (es)
EP (1) EP4003987A4 (es)
JP (1) JP2022542390A (es)
KR (1) KR20220041121A (es)
CN (1) CN114206862A (es)
AU (1) AU2020321067A1 (es)
BR (1) BR112022000944A2 (es)
CA (1) CA3147005A1 (es)
MX (1) MX2022001271A (es)
WO (1) WO2021018239A1 (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10013126A1 (de) * 2000-03-17 2001-09-20 Bayer Ag Arzneimittel gegen virale Erkrankungen
CN104603125A (zh) * 2012-09-10 2015-05-06 弗·哈夫曼-拉罗切有限公司 用于治疗和预防乙型肝炎病毒感染的6-氨基酸杂芳基二氢嘧啶
WO2017011552A1 (en) * 2015-07-13 2017-01-19 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
WO2017064156A1 (en) * 2015-10-16 2017-04-20 F. Hoffmann-La Roche Ag Novel 6-fused and 2-heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
CA3053818A1 (en) * 2017-03-01 2018-09-07 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders
EP3645516A4 (en) * 2017-06-27 2021-07-07 Janssen Pharmaceutica NV HETEROARYLDIHYDROPYRIMIDE DERIVATIVES AND METHODS OF TREATMENT OF HEPATITIS B INFECTIONS

Also Published As

Publication number Publication date
CA3147005A1 (en) 2021-02-04
CN114206862A (zh) 2022-03-18
EP4003987A4 (en) 2023-07-26
KR20220041121A (ko) 2022-03-31
US20220267313A1 (en) 2022-08-25
JP2022542390A (ja) 2022-10-03
AU2020321067A1 (en) 2022-03-24
WO2021018239A1 (en) 2021-02-04
BR112022000944A2 (pt) 2022-03-08
EP4003987A1 (en) 2022-06-01

Similar Documents

Publication Publication Date Title
DOP2021000147A (es) Combinacion terapeutica que comprende lamivudina
NZ733174A (en) Quinazoline derivatives used to treat hiv
WO2016196776A3 (en) Inhibitors of bruton's tyrosine kinase
NZ735575A (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
NZ732391A (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
WO2016004305A3 (en) Inhibitors of bruton's tyrosine kinase
MX2023000796A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
NZ741957A (en) Therapeutic compositions for treatment of human immunodeficiency virus
EP4342473A3 (en) Compounds useful in hiv therapy
MX2017003928A (es) Composiciones farmaceuticas de accion prolongada.
MX2021010145A (es) Derivados de amida utiles en el tratamiento de una infeccion por vhb o de enfermedades inducidas por vhb.
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MD3359146T2 (ro) Compoziții farmaceutice și utilizări direcționate spre bolile de depozitare lizozomală
WO2016086153A3 (en) Use of hsp90 inhibitors for the treatment of hiv infections and aids
MX2022001261A (es) Derivados de dihidropirimidina y usos de los mismos en el tratamiento de infeccion por vhb o de enfermedades inducidas por vhb.
MX2023004188A (es) Compuestos fosfolipidos y usos de estos.
EP3814326A4 (en) DIHYDROPYRIMIDE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR HBV-INDUCED DISEASE
EP3790866A4 (en) DIHYDROPYRIMIDE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR HBV-INDUCED DISEASE
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX2020001256A (es) Compuestos para la prevencion y el tratamiento de trastornos medicos y usos de los mismos.
PH12018500450A1 (en) Immunity enhancing agent for cancer by allergin-1 antagonist
MX2022001266A (es) Derivados de dihidropirimidina y usos de estos en el tratamiento de la infeccion por vhb o de enfermedades inducidas por vhb.
MX2018011095A (es) Compuestos de carbapenem.
MA40805A (fr) Compositions pharmaceutiques à action prolongée contre l'hépatite c
MX2022001271A (es) Derivados de dihidropirimidina y usos de estos en el tratamiento de la infeccion por vhb o de enfermedades inducidas por vhb.